Sandoz to pay up to $77 mln for three biosimilar drug rights from Shanghai Henlius Biotech

Sandoz to pay up to $77 mln for three biosimilar drug rights from Shanghai Henlius Biotech
Read more at the source

Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.